Nectar Lifesciences Limited
All news and filings related to Nectar Lifesciences Limited.
View all news & filings- Low impact
Nectar Lifesciences to hold 31st AGM on Sep 18, 2026, via VC/OAVM
Nectar Lifesciences Limited will hold its 31st AGM on September 18, 2026, via video conference. Remote e-voting will be open from September 15 to September 17, 2026. The cut-off date for e-voting is September 11, 2026. Annual Report for FY2025-26 is available online.
Read the summary - Low impact
Nectar Lifesciences Ltd. Publishes AGM Notice and E-voting Information
Nectar Lifesciences Limited has published the notice for its 31st Annual General Meeting (AGM), including e-voting and book closure details. The information was published in Business Standard and Desh Sewak on August 21, 2026, in compliance with regulatory requirements.
Read the summary - Low impact
Nectar Lifesciences Ltd. Announces 31st AGM on September 18, 2026
Nectar Lifesciences Limited will hold its 31st AGM on September 18, 2026, via Video Conference. Remote e-voting is open from September 15 to September 17, 2026. The AGM will consider financial statements for FY26 and re-appointments of directors, including Mr. Sanjiv Goyal, Dr. Kuldip Kumar Bhasin, Dr. Indu Pal Kaur, and the appointment of Dr. Gunmala Suri.
Read the summary - Low impact
Nectar Lifesciences Announces 31st AGM on Sep 18, 2026, via VC/OAVM
Nectar Lifesciences Limited will hold its 31st Annual General Meeting (AGM) on September 18, 2026. The meeting will be conducted via Video Conferencing (VC)/Other Audio-Visual Means (OAVM). The notice was published in Business Standard and Desh Sewak on August 20, 2026.
Read the summary - Low impact
Nectar Lifesciences Publishes Q1 FY27 Financial Results
Nectar Lifesciences Limited published its financial results for the quarter ended June 30, 2026. The results were announced on August 15, 2026, and published in Business Standard and Desh Sewak newspapers. The company provided a detailed extract of its financial performance for the quarter.
Read the summary - Low impact
Nectar Lifesciences Changes Corporate Office to Godrej Eternia, Chandigarh
Nectar Lifesciences Limited is relocating its corporate office to Godrej Eternia, West Wing (Tower A), Plot No. 70, Industrial Area, Phase -1, Chandigarh, 160 002. The change, approved by the board on August 14, 2026, will be effective from September 15, 2026.
Read the summary - Low impact
Nectar Lifesciences Ltd. Announces Book Closure for 31st AGM on Sep 18
Nectar Lifesciences Limited has set September 18, 2026, as the date for its 31st Annual General Meeting. The company's share transfer books will be closed from September 12 to September 18, 2026. The cut-off date for e-voting eligibility is September 11, 2026.
Read the summary - Medium impact
Nectar Lifesciences Board Approves Q1 FY27 Results, Appoints Director, Schedules AGM
Nectar Lifesciences approved Q1 FY27 unaudited financial results. The board appointed Dr. Gunmala Suri as Additional Director from August 15, 2026. The 31st AGM is scheduled for September 18, 2026. The company reported consolidated net loss of ₹1,313.52 lakhs for the quarter ended June 30, 2026.
Read the summary - Medium impact
Nectar Lifesciences Board Approves Q1 FY27 Results, Appoints New Director, Sets AGM Date
Nectar Lifesciences approved Q1 FY27 results with a net loss of ₹1,345.62 lakhs (standalone). Dr. Gunmala Suri appointed Additional Director from August 15, 2026. The 31st AGM is scheduled for September 18, 2026. The company also reported a ₹2,513.29 lakhs loss from market investments.
Read the summary - Low impact
Nectar Lifesciences Announces Resignation of Non-Executive Director Dr. Surulichamy Senthilkumar
Dr. Surulichamy Senthilkumar has resigned as a Non-Executive Non-Independent Director of Nectar Lifesciences Limited. The resignation is effective from August 06, 2026. The company has filed the necessary disclosures with the stock exchanges.
Read the summary - Low impact
Nectar Lifesciences Sells Non-Core Jammu Assets for ₹11.22 Crore
Nectar Lifesciences Limited sold its non-core Narbada Industries assets in Jammu for a total consideration of ₹11.22 crore. The sale includes leasehold rights for land and structures for ₹9.60 crore and plant and machinery for ₹1.62 crore. The transaction was completed on August 04, 2026.
Read the summary - Low impact
Nectar Lifesciences Extends Slump Sale Completion Date to Dec 31, 2026
Nectar Lifesciences Limited and Capnest Health Care Private Limited have mutually agreed to extend the completion date for the slump sale of the Empty Hard Gelatin Capsule business. The new expected completion date is now on or before December 31, 2026. Previous disclosures remain unchanged.
Read the summary - Low impact
Nectar Lifesciences Shifts Registered Office Effective July 15, 2026
Nectar Lifesciences Limited is shifting its registered office to Showroom no. 8, First Floor, Patiala Complex, Barwala Road, Dera Bassi, Punjab. The change is effective July 15, 2026. This move is within the same city and state and does not affect operations.
Read the summary - Low impact
Nectar Lifesciences Files SEBI Compliance Certificate for Q1 FY27
Nectar Lifesciences Limited submitted a compliance certificate for the quarter ended June 30, 2026, as required by SEBI regulations. The certificate from Kfin Technologies Limited confirms the proper processing of dematerialized securities.
Read the summary - Low impact
Nectar Lifesciences Ltd. Publishes Notice on IEPF Share Transfer
Nectar Lifesciences Limited is transferring equity shares with unpaid dividends for seven consecutive years to the IEPF. Unclaimed dividends from FY 2018-19 are also being transferred. The notice was published on June 16, 2026, in Business Standard and Desh Sewak.
Read the summary - Medium impact
Nectar Lifesciences Publishes Q4 & FY26 Financial Results
Nectar Lifesciences Limited announced its audited financial results for the quarter and year ended March 31, 2026. For the year, total income was ₹16,337.32 Lakhs and net loss was ₹53,765.51 Lakhs. For the quarter, total income was ₹5,691.96 Lakhs and net loss was ₹13,008.90 Lakhs. EPS for the year was ₹(11.72).
Read the summary - Medium impact
Nectar Lifesciences Board Approves FY26 Results, Reappoints Directors
Nectar Lifesciences reported audited financial results for FY26. The Board approved the re-appointment of Dr. Kuldip Kumar Bhasin and Dr. Indu Pal Kaur as Independent Directors. The company also withdrew the proposal for a new RTA and updated its policies.
Read the summary - Low impact
Nectar Lifesciences Extends Hard Gelatin Capsule Business Slump Sale Completion to July 31, 2026
Nectar Lifesciences Limited and Capnest Health Care Private Limited have mutually agreed to extend the completion date for the slump sale of the Empty Hard Gelatin Capsule business. The new expected completion date is now on or before July 31, 2026.
Read the summary - Low impact
Nectar Lifesciences Wins Income Tax Litigation for AY 2017-18; Case Concluded
Nectar Lifesciences Limited won a key income tax litigation for assessment year 2017-18. The DCIT, Chandigarh, issued an order on March 31, 2026, concluding the matter in the company's favor. This follows earlier favorable High Court rulings. The company apologized for a delay in disclosure.
Read the summary - Low impact
Nectar Lifesciences Launches 'Saksham Niveshak' Campaign for Investor Outreach
Nectar Lifesciences Limited launched the 'Saksham Niveshak' campaign from April 01, 2026, to July 09, 2026. The initiative helps investors update KYC details and claim unpaid dividends. This aims to prevent transfer of funds and shares to the IEPF Authority. Investors are encouraged to update their information promptly.
Read the summary - Low impact
Nectar Lifesciences Files Certificate Under SEBI Depositories and Participants Regulations
Nectar Lifesciences Limited submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018. The certificate from Kfin Technologies Limited covers the quarter ended March 31, 2026, confirming dematerialization processes and updates to the register of members.
Read the summary - Low impact
Nectar Lifesciences: Trading Window Closed from April 1, 2026, for Financial Results
Nectar Lifesciences Limited will close its trading window from April 1, 2026, for designated persons and relatives. The window will reopen 48 hours after the declaration of financial results for the period ending March 31, 2026, in compliance with SEBI regulations.
Read the summary - Medium impact
Nectar Lifesciences Faces Litigation Challenge: CGST Ludhiana Files Writ Petition
Nectar Lifesciences faces a civil writ petition filed by CGST Ludhiana challenging a prior appellate order. The petition disputes the dropping of a ₹89.32 crore demand and the remand of a ₹6.24 crore demand. The company contests the petition, with a hearing scheduled for April 28, 2026. Potential liability could be significant.
Read the summary - Medium impact
Nectar Lifesciences Shareholders Approve Director Appointments and MOA Amendments via Postal Ballot
Nectar Lifesciences shareholders approved the appointment of Sushil Kapoor as Director and Director (Finance) for three years. They also approved amendments to the MOA. Voting concluded on February 28, 2026, with results declared on March 1, 2026.
Read the summary - Medium impact
Nectar Lifesciences Lends ₹100 Crore to Wholly Owned Subsidiary Avensis Exports
Nectar Lifesciences Limited has provided an inter-corporate loan of up to ₹100 crore to its wholly-owned subsidiary, Avensis Exports Private Limited. The loan has a 10-year tenure and carries an interest rate of 12% per annum. The funds will be used for AEPL's general corporate purposes.
Read the summary - Low impact
Nectar Lifesciences Wins Case, Mumbai Court Returns Plaint Against Company
Nectar Lifesciences Limited has won a legal battle as the Mumbai City Civil Commercial Court returned a plaint filed by Sanjay Chemicals India Private Limited. The plaintiff sought recovery of ₹ 43,30,914 plus interest and penalty. The court dismissed the case due to lack of jurisdiction and time-barring of claims.
Read the summary - Medium impact
Nectar Lifesciences Acquires 100% Stake in Avensis Exports Pvt. Ltd. for ₹24.96 Lakhs
Nectar Lifesciences Limited has acquired 100% of Avensis Exports Private Limited (AEPL) for a cash consideration of ₹24.96 Lakhs. The acquisition was completed on March 06, 2026, making AEPL a wholly-owned subsidiary of Nectar Lifesciences.
Read the summary - Medium impact
Nectar Lifesciences to Infuse ₹120 Cr as Loan to Wholly Owned Subsidiary
Nectar Lifesciences Limited's board approved infusing up to ₹120 crores as an inter-corporate loan to its proposed wholly owned subsidiary, Avensis Exports Private Limited. This decision was made during a board meeting on March 02, 2026. Further details on the loan agreement will be disclosed post-acquisition and finalization of definitive agreements.
Read the summary - Medium impact
Nectar Lifesciences to Acquire 100% Stake in Avensis Exports, Change RTA
Nectar Lifesciences will acquire 100% of Avensis Exports Private Limited for ₹24.96 lakh to enter the real estate business. The company also decided to change its RTA from KFin Technologies to Alankit Assignments to improve efficiency and reduce costs. The acquisition is expected within a month.
Read the summary - Medium impact
Nectar Lifesciences to acquire 100% stake in Avensis Exports for ₹24.96 Lakh, shifts RTA
Nectar Lifesciences will acquire 100% of Avensis Exports Private Limited (AEPL) for ₹24.96 Lakh to enter the real estate business. The acquisition is expected to complete within one month. Additionally, the company is changing its RTA from KFin Technologies to Alankit Assignments to improve efficiency and investor services.
Read the summary - Medium impact
Nectar Lifesciences Shareholders Approve Director Appointment & MOA Amendments
Nectar Lifesciences shareholders approved the appointment of Mr. Sushil Kapoor as a Wholetime Director (Finance) for three years. They also approved amendments to the company's Memorandum of Association. The postal ballot results were finalized on February 28, 2026.
Read the summary - Low impact
Nectar Lifesciences Clarifies Financial Results for Q2 FY26, Standalone and Consolidated Figures Match
Nectar Lifesciences Limited clarified that its standalone and consolidated financial results for the quarter ended September 30, 2025, are identical. This is due to its wholly-owned subsidiary being inactive with no financial activity. The company confirmed this aligns with the independent auditors' review.
Read the summary - Low impact
Nectar Lifesciences Ltd. Publishes Newspaper Notice for Postal Ballot and E-voting
Nectar Lifesciences Limited is conducting a postal ballot and e-voting for members. Key resolutions include appointing Mr. Sushil Kapoor as Director (Finance) and adopting an amended Memorandum of Association. E-voting runs from January 30 to February 28, 2026. Results will be announced on March 2, 2026.
Read the summary - Medium impact
Nectar Lifesciences Ltd. Announces Postal Ballot for Director Appointments and MOA Amendment
Nectar Lifesciences Ltd. is conducting a postal ballot to approve Mr. Sushil Kapoor's appointment as Director (Finance) for three years from December 4, 2025, with a ₹3 lakh monthly salary. Members will also vote on adopting an amended MOA. Remote e-voting is open from January 30 to February 28, 2026.
Read the summary - Medium impact
Nectar Lifesciences Promoter Shareholding Increases Post Buyback
Nectar Lifesciences Limited promoters' shareholding increased post buyback. Total promoter group stake rose from 44.91% to 51.84%. Sanjiv Goyal's stake increased to 24.63%, Sanjiv (HUF) to 22.46%, and Raman Goyal to 4.76%. This follows a buyback from Dec 31, 2025, to Jan 06, 2026.
Read the summary - Low impact
Nectar Lifesciences Ltd. Publishes Q3 FY26 Financial Results
Nectar Lifesciences Limited published its financial results for the quarter and nine months ended December 31, 2025. The results were published in Business Standard and Desh Sewak on January 24, 2026. The detailed financial results are available on the company's website and stock exchange portals.
Read the summary - Low impact
Nectar Lifesciences Board Approves MOA Update and Appoints Internal Auditors
Nectar Lifesciences' board approved an updated MOA to expand business into construction and real estate, pending shareholder approval. M/s. VDR & Associates were appointed as Internal Auditors for FY25-26 and FY26-27. Shareholder approval for the MOA will be sought via postal ballot.
Read the summary - High impact
Nectar Lifesciences posts Q3 FY26 results, details pharma business sale & buyback.
Nectar Lifesciences reported Q3 FY26 results after a board meeting on January 23, 2026. The company finalized the sale of its Pharma Business and Menthol Assets for ₹125,398.55 lakhs, recognizing an ₹8,815.13 lakhs profit. A sale of the Capsule Business for ₹1,990.00 lakhs is pending approval. A ₹8,100.00 lakhs share buyback was completed.
Read the summary - Medium impact
Nectar Lifesciences Completes Share Buyback, Extinguishes 3 Crore Shares
Nectar Lifesciences Limited has completed its buyback of 3 crore equity shares at ₹27 per share, with settlement on January 13, 2026. The company is now extinguishing these shares. A post-buyback announcement was published on January 15, 2026.
Read the summary - Low impact
Nectar Lifesciences Files Certificate Under SEBI Regulations for Q3FY26
Nectar Lifesciences Limited submitted a certificate for the quarter ended December 31, 2025, as per SEBI regulations. The certificate from Kfin Technologies confirms processing of dematerialized securities during the period. This is a routine compliance filing.
Read the summary - Low impact
Nectar Lifesciences Ltd. Publishes Newspaper Advertisement for Letter of Offer Dispatch
Nectar Lifesciences Limited published a newspaper advertisement on December 30, 2025, concerning the dispatch of its Letter of Offer for the buyback of equity shares. The advertisement appeared in Business Standard (English & Hindi) and Desh Sewak (Punjabi).
Read the summary - Medium impact
Nectar Lifesciences Announces Buyback of 3 Crore Shares at ₹27 Each
Nectar Lifesciences Limited is undertaking a buyback of 3 crore equity shares at ₹27 per share, totaling ₹81 crore. The buyback opens on December 31, 2025, and closes on January 6, 2026. The record date was December 24, 2025. This represents 13.38% of the equity capital.
Read the summary - Low impact
Nectar Lifesciences: Trading Window Closed Jan 1, 2026, for Q3 FY26 Results
Nectar Lifesciences Limited will close its trading window for designated persons from January 01, 2026. This closure is in anticipation of the financial results for the quarter ending December 31, 2025, and will last until 48 hours after their announcement.
Read the summary - Low impact
Nectar Lifesciences Sells Capsule Unit for ₹19.9 Crore
Nectar Lifesciences Limited sold its Empty Hard Gelatin Capsule unit to Capnest Health Care Private Limited for ₹19.90 crore. The sale is expected to be completed by April 30, 2026. The unit contributed 1.28% to the company's FY25 revenue. Proceeds will be used for strategic investments and general corporate purposes.
Read the summary - Low impact
NECLIFE Announces Corrigendum for Buyback of Equity Shares
Nectar Lifesciences announced a corrigendum to its buyback announcement, published in multiple newspapers on December 10, 2025, following an earlier disclosure on December 5, 2025.
Read the summary - Medium impact
NECLIFE Announces Buyback of Shares worth ₹81 Crore
Nectar Lifesciences Limited announced a buyback of its equity shares for ₹81 crore at ₹27 per share via tender offer. Record date is December 24, 2025. Promoters will not participate.
Read the summary - Medium impact
NECLIFE Announces Buyback of Shares & Appointment of Additional Director
Nectar Lifesciences announces a buyback of 3 crore shares at ₹27 per share, totaling ₹81 crore. Sushil Kapoor appointed as Additional and Wholetime Director, subject to shareholder approval.
Read the summary - Medium impact
NECLIFE Announces Buyback of Shares and Appointment of Additional Director
Nectar Lifesciences announces a buyback of 3 crore shares at ₹27 per share, totaling ₹81 crore, and appoints Mr. Sushil Kapoor as an additional and Wholetime Director.
Read the summary - Medium impact
NECLIFE Announces Buyback of Shares and Appointment of Director
Nectar Lifesciences announces a buyback of 3 crore shares at ₹27 per share, totaling ₹81 crore, and appoints Sushil Kapoor as an Additional Director and Wholetime Director (Finance).
Read the summary - Low impact
Disclosure under Insider Trading Regulations
Promoter Sanjiv Goyal disposed of 80,00,000 shares via gift, while Raman Goyal acquired the same amount, changing their holdings on 27 Nov 2025.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio